Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06873945 · ClinicalTrials.gov registry record · Phase 3

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

A Phase 3 study of Alopecia Areata, sponsored by Pfizer.

Recruiting
Registry status
Phase 3
Development phase
550
Enrollment target
20
Study locations

NCT06873945: Recruiting Phase 3 study of Alopecia Areata, sponsored by Pfizer.

NCT06873945 is a Phase 3 study of Alopecia Areata that is actively recruiting participants, run by Pfizer. The registered enrollment target is 550 participants, below the 1,934-participant average among 26 other Alopecia Areata trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06873945, a Phase 3 study of Alopecia Areata, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 3
Development phase
550 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose. This study is seeking participants who: * Are 12 years of age or older * Have a diagnosis of alopecia areata * Have lost 50% or more of the hair on their scalp * Do not have any other conditions that causes hair loss * Are willing to stop all other treatments that they may be taking for alopecia areata About 550 participants will take part in in this study. Participants will be chosen by chance, like drawing names out of a hat, to receive 1 of 2 different amounts of ritlecitinib (50 mg and 100 mg) taken by mouth once daily. The 2 doses of ritlecitinib in this study will be compared to each other and also to data from previous studies. This will help to see if the 100 mg dose of ritlecitinib is safe and effective. People will be in this study for about 13 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as: * alopecia areata assessment, * physical examinations, * hearing tests, * blood tests, * x-ray, * ECG (electrocardiogram), * photographs of the scalp and eyes. Participants will also be asked to complete questionnaires about their alopecia areata.

Primary Outcome

Difference in the percentage of participants with SALT score less than or equal to 20 between ritlecitinib 100 mg once-daily (QD) versus placebo

Conditions Studied

Alopecia Areata

Interventions

  • DRUG Ritlecitinib 50 mg
  • DRUG Ritlecitinib 100 mg
  • DRUG Placebo - 50 mg
  • DRUG Placebo - 100 mg

Study Locations (20)

Florida

  • Alliance for Multispecialty Research, LLC - Fort Myers
  • Robert B. Pritt, DO, PA - Fort Myers
  • Solutions Through Advanced Research - Jacksonville
  • Pediatric Skin Research - Miami
  • Skin Research of South Florida - Miami
  • ForCare Clinical Research - Tampa
  • Olympian Clinical Research - Tampa - Memorial Highway - Tampa

California

  • Doc1 Healthcare Systems - Brea
  • California Dermatology & Clinical Research Institute - Encinitas
  • Marvel Clinical Research - Huntington Beach
  • Southern California Clinical Research - Santa Ana

Indiana

  • Indiana University Health University Hospital Adult Outpatient Center - Indianapolis
  • Indiana University School of Medicine - Indiana CTSI Clinical Research Center - Indianapolis
  • Sidney & Lois Eskenazi Health Center - Indianapolis
  • Dawes Fretzin Clinical Research Group, LLC - Indianapolis

Arkansas

  • Burke Pharmaceutical Research - Hot Springs

Connecticut

  • Brett King MD, LLC - Fairfield

Illinois

  • Endeavor Health - Skokie

Iowa

  • University of Iowa - Iowa City

Maryland

  • Callender Center for Clinical Research - Glenn Dale

Trial Details

FieldValue
Enrollment Target 550 participants
Start Date 2025-04-01
Est. Completion 2027-03-09
Phase Phase 3
Pfizer

1,845 total trials

What NCT06873945 shows while recruiting

NCT06873945 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, below the 1,934-participant average among 26 other Alopecia Areata trials with a reported enrollment target (72% lower).

The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 4 interventions - of which Ritlecitinib 50 mg is the first listed.

NCT06873945 names 20 study sites across 8 states, led by Florida, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT06873945 about?

NCT06873945 is a clinical study titled "A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata". The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 5...

What is the current status of trial NCT06873945?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2025-04-01. Estimated completion is 2027-03-09.

What conditions does trial NCT06873945 study?

This clinical trial studies the following conditions: Alopecia Areata.

What interventions are being tested in trial NCT06873945?

The interventions under investigation include: Ritlecitinib 50 mg (DRUG), Ritlecitinib 100 mg (DRUG), Placebo - 50 mg (DRUG), Placebo - 100 mg (DRUG).

Who is sponsoring clinical trial NCT06873945?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06873945 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alopecia Areata

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06873945's enrollment target sits among peer trials

550 10th of 26 higher than 17 of 26 other Alopecia Areata trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alopecia Areata trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01852448 · 550 participants

    Genetics of Insulin and Incretins in Cystic Fibrosis

  • NCT02995252 · 550 participants

    The HOPE Study: Characterizing Patients With Hepatitis B and C

  • NCT03474913 · 550 participants

    Upright MRI for Prostate Cancer Screening

  • NCT04761120 · 550 participants

    Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06873945

Source: ClinicalTrials.gov NCT06873945, the US trial registry maintained by the National Library of Medicine. NCT06873945 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.